ArticleOrphanet journal of rare diseases2026
Lower mitochondrial DNA copy number in ATTRV50M Swedish carriers.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHereditary transthyretin (TTR) amyloidosis caused by TTR p.Val50Met (ATTRV50M) is a progressive systemic disease caused by misfolding of the protein transthyretin (TTR). The conversion of TTR into an amyloidogenic state has recently been found to be strongly influenced by a non-native disulfide bond, thus also a redox environment. Variation in mitochondrial DNA (mtDNA) copy number serves as an indirect marker of redox imbalance and mitochondrial dysfunction. MtDNA is moreover strictly maternally inherited, supporting previous findings where maternal inheritance of the pathogenic variant also results in both a more severe disease and an earlier onset. Considering these aspects, we aimed to investigate mtDNA levels in Swedish TTRp.Val50Met carriers.
methods304 individuals were divided into three groups: symptomatic and asymptomatic TTR p.Val50Met carriers, and healthy non-carrier controls. Relative mtDNA copy number was quantified from buffy coat samples using multiplex qPCR.
resultsSymptomatic TTR p.Val50Met carriers showed a significantly lower copy number (p = 0.002) compared to the asymptomatic carriers. When stratified by sex, a significantly lower mtDNA copy number in symptomatic compared to asymptomatic carriers was observed only among males (p = 0.028). Furthermore, a significant difference in copy number (< 0.001) could be demonstrated in ≥ 50 year-olds (considered late onset in Swedish ATTRV50M population) betweensymptomatic and asymptomatic TTR p.Val50Met carriers, which could not be seen in < 50 year-olds (Swedish early onset).
conclusionThese findings indicate an association between lower mtDNA copy numbers and symptomatic disease in Swedish TTR p.Val50Met carriers, suggesting potential mitochondrial involvement in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.